TABLE 2.
Immunotherapy agent | Number of patients, n = 155 (%) |
---|---|
Nivolumab | 151 (97.4) |
Pembrolizumab | 4 (2.6) |
Nivolumab dose | |
3 mg/kg every 2 weekly | 108 (69.7) |
240 mg flat dose every 2 weekly | 47 (30.3) |
Pembrolizumab‐ 200 mg flat dose every 3 weekly | 4 (2.6) |